Cargando…
ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis
Fibrogenic progression of chronic liver disease, whatever the etiology, is characterized by persistent chronic parenchymal injury, chronic activation of inflammatory response, and sustained activation of liver fibrogenesis, and of pathological wound healing response. A critical role in liver fibroge...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600376/ https://www.ncbi.nlm.nih.gov/pubmed/31159366 http://dx.doi.org/10.3390/ijms20112700 |
_version_ | 1783431102514331648 |
---|---|
author | Foglia, Beatrice Cannito, Stefania Bocca, Claudia Parola, Maurizio Novo, Erica |
author_facet | Foglia, Beatrice Cannito, Stefania Bocca, Claudia Parola, Maurizio Novo, Erica |
author_sort | Foglia, Beatrice |
collection | PubMed |
description | Fibrogenic progression of chronic liver disease, whatever the etiology, is characterized by persistent chronic parenchymal injury, chronic activation of inflammatory response, and sustained activation of liver fibrogenesis, and of pathological wound healing response. A critical role in liver fibrogenesis is played by hepatic myofibroblasts (MFs), a heterogeneous population of α smooth-muscle actin—positive cells that originate from various precursor cells through a process of activation and transdifferentiation. In this review, we focus the attention on the role of extracellular signal-regulated kinase (ERK) signaling pathway as a critical one in modulating selected profibrogenic phenotypic responses operated by liver MFs. We will also analyze major therapeutic antifibrotic strategies developed in the last two decades in preclinical studies, some translated to clinical conditions, designed to interfere directly or indirectly with the Ras/Raf/MEK/ERK signaling pathway in activated hepatic MFs, but that also significantly increased our knowledge on the biology and pathobiology of these fascinating profibrogenic cells. |
format | Online Article Text |
id | pubmed-6600376 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66003762019-07-16 ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis Foglia, Beatrice Cannito, Stefania Bocca, Claudia Parola, Maurizio Novo, Erica Int J Mol Sci Review Fibrogenic progression of chronic liver disease, whatever the etiology, is characterized by persistent chronic parenchymal injury, chronic activation of inflammatory response, and sustained activation of liver fibrogenesis, and of pathological wound healing response. A critical role in liver fibrogenesis is played by hepatic myofibroblasts (MFs), a heterogeneous population of α smooth-muscle actin—positive cells that originate from various precursor cells through a process of activation and transdifferentiation. In this review, we focus the attention on the role of extracellular signal-regulated kinase (ERK) signaling pathway as a critical one in modulating selected profibrogenic phenotypic responses operated by liver MFs. We will also analyze major therapeutic antifibrotic strategies developed in the last two decades in preclinical studies, some translated to clinical conditions, designed to interfere directly or indirectly with the Ras/Raf/MEK/ERK signaling pathway in activated hepatic MFs, but that also significantly increased our knowledge on the biology and pathobiology of these fascinating profibrogenic cells. MDPI 2019-06-01 /pmc/articles/PMC6600376/ /pubmed/31159366 http://dx.doi.org/10.3390/ijms20112700 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Foglia, Beatrice Cannito, Stefania Bocca, Claudia Parola, Maurizio Novo, Erica ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis |
title | ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis |
title_full | ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis |
title_fullStr | ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis |
title_full_unstemmed | ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis |
title_short | ERK Pathway in Activated, Myofibroblast-Like, Hepatic Stellate Cells: A Critical Signaling Crossroad Sustaining Liver Fibrosis |
title_sort | erk pathway in activated, myofibroblast-like, hepatic stellate cells: a critical signaling crossroad sustaining liver fibrosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600376/ https://www.ncbi.nlm.nih.gov/pubmed/31159366 http://dx.doi.org/10.3390/ijms20112700 |
work_keys_str_mv | AT fogliabeatrice erkpathwayinactivatedmyofibroblastlikehepaticstellatecellsacriticalsignalingcrossroadsustainingliverfibrosis AT cannitostefania erkpathwayinactivatedmyofibroblastlikehepaticstellatecellsacriticalsignalingcrossroadsustainingliverfibrosis AT boccaclaudia erkpathwayinactivatedmyofibroblastlikehepaticstellatecellsacriticalsignalingcrossroadsustainingliverfibrosis AT parolamaurizio erkpathwayinactivatedmyofibroblastlikehepaticstellatecellsacriticalsignalingcrossroadsustainingliverfibrosis AT novoerica erkpathwayinactivatedmyofibroblastlikehepaticstellatecellsacriticalsignalingcrossroadsustainingliverfibrosis |